Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Exploring the use of atezolizumab in combination with R-CHOP in DLBCL

Anas Younes • 2 Dec 2018
ASH 2018
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Atezolizumab Checkpoint inhibitors

After the successful use of PD-L1 inhibitors in solid tumors, these agents are now being explored in diffuse large B-cell lymphoma (DLBCL). Here, Anas Younes, MD, of Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the preliminary analysis of a Phase I/II study on the use of atezolizumab in combination with R-CHOP in patients with DLBCL (NCT02596971). Presented at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

More from Anas Younes

1:01
Fimepinostat with venetoclax in R/R lymphoma
Anas Younes • 7 Dec 2019
1:27
Atezolizumab plus R-CHOP in DLBCL: encouraging results
Anas Younes • 7 Dec 2019
1:42
Dual inhibition of BCL2 and MCL1 using tumor targeted nanoparticles in lymphoma
Anas Younes • 7 Dec 2019
2:55
Ibrutinib in combination with R-CHOP in DLBCL: does age make a difference?
Anas Younes • 6 Dec 2018

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals